Loading…
Loading…
QNNTF (Quantum Genomics S.A.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
QNNTF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for QNNTF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for QNNTF and 80,000+ other tickers.
See exactly how QNNTF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for QNNTF and 80,000+ other tickers.
Quantum Genomics S.A., a biopharmaceutical enterprise headquartered in Paris, France, was established in 2005. The company specializes in advancing therapeutic solutions for cardiovascular ailments. Its drug development efforts are anchored in the brain aminopeptidase A inhibition (BAPAI) platform, primarily targeting hypertension (high blood pressure) and heart failure. Among its pipeline, firibastat is a notable candidate, currently undergoing a crucial Phase III study as a standalone treatment for high blood pressure, and is also progressing through clinical trials for heart failure…
Quantum Genomics (OTCMKTS:QNNTF - Get Free Report) and TELA Bio (NASDAQ: TELA - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, earnings and analyst recommendations. Earnings and Valuation This table compares Quantum Genomics
PARIS, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a new class of drugs which act directly on the brain to treat difficult-to-treat/resistant hypertension and heart failure, announces the start of its pivotal REFRESH study in Asia.
PARIS, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and resistant hypertension and heart failure, today announced results of the Phase IIb QUORUM study were presented by Prof. Gilles Montalescot (Paris) on August 27, 2021 during the 2021 scientific sessions of the European Society of Cardiology (ESC).
PARIS, July 08, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and resistant hypertension and heart failure, today announced the enrollment of the first patient in the Company's REFRESH study ( R andomized study of E xtended treatment with F iribastat in treatment- RES istant H ypertension) in difficult-to-treat(1) or resistant(2) hypertension. The study is being conducted jointly with its partners DongWha for South-Korea and Orient Europharma for South-East-Asia, Australia and New Zeland.